Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Ann Oncol. 2018. PMID: 30202892 Free article. Review.
Lymph node yield: Impact on oncologic outcomes in oral cavity cancer.
Khalil C, Khoury M, Higgins K, Enepekides D, Karam I, Husain ZA, Bayley A, Poon I, Truong T, Chan KKW, Smoragiewicz M, Fu R, Eskander A. Khalil C, et al. Among authors: smoragiewicz m. Head Neck. 2024 Aug;46(8):1965-1974. doi: 10.1002/hed.27656. Epub 2024 Feb 12. Head Neck. 2024. PMID: 38344842
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S, Mason W, MacNeil M, Harlos C, Tsang R, Sederias J, Luchman HA, Weiss S, Rossiter JP, Tu D, Seymour L, Smoragiewicz M. Lapointe S, et al. Among authors: smoragiewicz m. Invest New Drugs. 2020 Aug;38(4):1137-1144. doi: 10.1007/s10637-019-00875-4. Epub 2019 Nov 9. Invest New Drugs. 2020. PMID: 31707687 Clinical Trial.
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
Smoragiewicz M, Adjei AA, Calvo E, Tabernero J, Marabelle A, Massard C, Tang J, de Vries EGE, Douillard JY, Seymour L; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Clin Cancer Res. 2020 Jun 1;26(11):2461-2465. doi: 10.1158/1078-0432.CCR-19-3136. Epub 2020 Feb 21. Clin Cancer Res. 2020. PMID: 32086344
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
Juergens RA, Hao D, Ellis PM, Tu D, Mates M, Kollmannsberger C, Bradbury PA, Tehfe M, Wheatley-Price P, Robinson A, Bebb G, Laskin J, Goffin J, Hilton J, Tomiak A, Hotte S, Goss GD, Brown-Walker P, Sun X, Tsao MS, Cabanero M, Gauthier I, Song X, Dennis PA, Seymour LK, Smoragiewicz M, Laurie SA. Juergens RA, et al. Among authors: smoragiewicz m. Lung Cancer. 2020 May;143:1-11. doi: 10.1016/j.lungcan.2020.02.016. Epub 2020 Feb 28. Lung Cancer. 2020. PMID: 32169783 Clinical Trial.
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
Wells JC, Sidhu A, Ding K, Smoragiewicz M, Heng DYC, Shepherd FA, Ellis PM, Bradbury PA, Jonker DJ, Siu LL, Gelmon KA, Karapetis C, Shapiro J, Nott L, O'Callaghan CJ, Parulekar WR, Seymour L, Monzon JG. Wells JC, et al. Among authors: smoragiewicz m. Oncologist. 2022 Mar 11;27(3):e286-e293. doi: 10.1093/oncolo/oyac020. Oncologist. 2022. PMID: 35274718 Free PMC article.
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
Nehra J, Bradbury PA, Ellis PM, Laskin J, Kollmannsberger C, Hao D, Juergens RA, Goss G, Wheatley-Price P, Hotte SJ, Gelmon K, Tinker AV, Brown-Walker P, Gauthier I, Tu D, Song X, Khan A, Seymour L, Smoragiewicz M. Nehra J, et al. Among authors: smoragiewicz m. Invest New Drugs. 2020 Oct;38(5):1442-1447. doi: 10.1007/s10637-020-00904-7. Epub 2020 Feb 4. Invest New Drugs. 2020. PMID: 32020438 Clinical Trial.
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Kroeger N, et al. Among authors: smoragiewicz m. Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15. Eur Urol. 2015. PMID: 25524810
31 results